Treating First-Line HCC With Immune Checkpoint Inhibition

Imaging suggests HCC, yet cirrhosis is uncertain—see why biopsy matters and how AFP, spread, and liver function shape treatment.

During a live event, Anthony B. El-Khoueiry, MD, discussed nivolumab plus ipilimumab vs lenvatinib/sorafenib in unresectable HCC.

During a live event, Anthony B. El-Khoueiry, MD, discussed downstaging for transplant and evolving frontline systemic therapies in advanced HCC.

During a live event, Mark Yarchoan, MD, and participants reviewed adverse event management for 3 different combination regimens for hepatocellular carcinoma.